There are currently 1248 clinical trials in Seattle, Washington looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Washington, Seattle Children's Hospital, Fred Hutchinson Cancer Research Center and University of Washington Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer
NCT05652868
Recruiting
This is a Phase I open label multi-center study to evaluate the safety, tolerability, pharmacokinetics and preliminary effectiveness of the investigational drug MYTX-011 in patients with locally advanced, recurrent or metastatic NSCLC. MYTX-011 is in a class of medications called antibody drug conjugates (ADCs). MYTX-011 is composed of a pH-dependent anti-cMET antibody and the potent antimicrotubule drug monomethyl auristatin E (MMAE).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Fred Hutchinson Cancer Center, Seattle, Washington
Conditions: NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer
Register for Updates
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
NCT06239467
Recruiting
OKI-219-101 is a Phase 1a/1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of OKI-219 as monotherapy and in combination with fulvestrant or trastuzumab. Phase 1a (Part A) will investigate escalating doses of OKI-219 monotherapy, and Phase 1b will investigate OKI-219 (at a tolerated dose determined in Part A) in combination with standard dose fulvestrant (Part B) or standard dose trastuzum... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Fred Hutchinson Cancer Center, Seattle, Washington
Conditions: Advanced Cancer, Breast Cancer
Register for Updates
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
NCT06551116
Recruiting
This study will assess whether a quantitative, HER2 assay can accurately and reliably discriminate between responders and non-responders among patients with HER2 IHCI+ metastatic breast cancer who are receiving T-Dxd.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: University of Washington - Fred Hutchinson Cancer Center, Seattle, Washington
Conditions: HER2-positive Metastatic Breast Cancer
Register for Updates
Cognitive Training and Neuroplasticity in Mild Cognitive Impairment: COGIT-2 Trial
NCT06601933
Recruiting
Effective, clinically meaningful treatments are lacking for patients with mild cognitive impairment (MCI), which is associated with increased risk of transition to dementia. Cognitive training represents an important therapeutic strategy. In a previous study, crossword puzzles were found to be superior to computerized cognitive training on the primary cognitive outcome and function with decreased brain atrophy. Building on these findings, this study will evaluate and compare the impact of high d... Read More
Gender:
ALL
Ages:
Between 55 years and 89 years
Trial Updated:
06/26/2025
Locations: University of Washington, Seattle, Washington
Conditions: Mild Cognitive Impairment (MCI), Cognitive Training
Register for Updates
Addressing Barriers to Care for Substance Use Disorder Trial
NCT06729957
Recruiting
The Addressing Barriers to Care for Substance Use Disorder Trial (ABC-SUD) is a cluster-randomized crossover trial, with clinicians (care coordinators) as the unit of randomization. This study will be conducted in a mental health access center within the Washington region of Kaiser Permanente. As part of usual care, patients contact the mental health access center and speak to a care coordinator to obtain an appointment with or contact information for potential venues to obtain treatment for su... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Kaiser Permanente Washington, Seattle, Washington
Conditions: Drug Use Disorders, Alcohol-Related Disorders, Substance Use Disorder (SUD)
Register for Updates
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
NCT04614103
Recruiting
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/25/2025
Locations: Seattle Cancer Care Alliance, Seattle, Washington
Conditions: Metastatic Non Small Cell Lung Cancer
Register for Updates
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
NCT05555732
Recruiting
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: VA Puget Sound Health Care System, Seattle, Washington
Conditions: Metastatic Non Small Cell Lung Cancer
Register for Updates
Benchmark Evidence Led by Latin America: Trial of Intracranial Pressure - Pediatrics
NCT05566431
Recruiting
Narrative: Worldwide, traumatic brain injury (TBI) is a leading cause of death and disability among children and adolescents. The Investigators aim to test whether pediatric TBI treatment guided by invasive intracranial pressure monitoring produces better patient outcomes than care guided by a protocol without invasive monitoring. Study findings will inform clinical practice in treating pediatric severe TBI globally. Focused didactic and experience-based learning opportunities will increase the... Read More
Gender:
ALL
Ages:
Between 1 year and 12 years
Trial Updated:
06/25/2025
Locations: University of Washington, Harborview Medical Center, Seattle, Washington
Conditions: Severe Traumatic Brain Injury
Register for Updates
Advancing Transplantation Outcomes in Children
NCT06055608
Recruiting
This is a pediatric kidney transplant study comparing the safety and efficacy of an immunosuppressive regimen of belatacept and sirolimus to tacrolimus and Mycophenolate Mofetil (MMF). Two hundred participants will be randomized (1:1) to one of two groups within 24 hours following the transplant procedure. The duration of the study from time of transplant to the primary endpoint is 12-24 months.
Gender:
ALL
Ages:
Between 13 years and 20 years
Trial Updated:
06/25/2025
Locations: Seattle Children's Hospital (Site #: 71041), Seattle, Washington
Conditions: Kidney Transplant
Register for Updates
FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT06609928
Recruiting
This phase I trial tests the safety, side effects, and best dose of FH-FOLR1 chimeric antigen receptor (CAR) T cells in treating pediatric patients with FOLR1+ acute myeloid leukemia (AML) that has come back after a period of improvement (recurrent) or has not responded to previous treatment (refractory). CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a pa... Read More
Gender:
ALL
Ages:
6 years and below
Trial Updated:
06/25/2025
Locations: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Conditions: Recurrent Childhood Acute Myeloid Leukemia, Refractory Childhood Acute Myeloid Leukemia
Register for Updates
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
NCT02523014
Recruiting
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Pacific Gynecology Specialists, Seattle, Washington +4 locations
Conditions: Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
Register for Updates
Clinical Study of Edwards Cardioband FIT Valve Repair System
NCT03382457
Recruiting
Clinical Study of the Edwards Cardioband FIT Repair System
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: University of Washington, Seattle, Washington
Conditions: Tricuspid Regurgitation
Register for Updates